A Phase 2, Multi-Center, Randomized Clinical Trial to Evaluate the Efficacy and Safety of Human Anti-SARS-CoV-2 Convalescent Plasma in Severely Ill Adults With COVID-19
收藏DataCite Commons2025-05-01 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/00007319/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
This randomized blinded multi-center phase 2 trial will assess the efficacy and safety of
anti-SARS-CoV-2 convalescent plasma among adults with severe COVID-19. Adults ≥18 years of
age may participate. A total of 219 eligible subjects will be randomized in a 2:1 ratio to
receive either high-titer anti-SARS-CoV-2 plasma or non-convalescent fresh frozen plasma
(control plasma).
提供机构：
Vivli
创建时间：
2021-08-09
